ARDELYX, INC. (ARDX) FY2025 10-K Annual Report
ARDELYX, INC. (ARDX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 19, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
ARDELYX, INC. FY2025 10-K Analysis
Business Overview
- • Core business model: Development and commercialization of innovative medicines focused on tenapanor-based therapies for gastrointestinal and kidney diseases
- • New emphasis on Phase 3 trial initiation in January 2026 for tenapanor in chronic idiopathic constipation (CIC), targeting a new patient population of 34 million Americans
Management Discussion & Analysis
- • Total revenue $407.3M, up 22% YoY from $333.6M in 2024; product sales $377.8M, up 18% YoY from $319.2M
- • Operating expenses $448.3M, up 24% YoY from $361.6M; cost of sales down 22% to $39.5M vs $50.6M; R&D up 37% to $71.5M; SG&A up 30% to $337.2M
Risk Factors
- • Regulatory risk: CMS inclusion of XPHOZAH in ESRD PPS on Jan 1, 2025, eliminated Medicare Part D coverage, materially reducing 2025 XPHOZAH revenue
- • Geopolitical/macro risk: Foreign price controls in Europe, Canada, Japan, China may limit IBSRELA and XPHOZAH pricing and reduce international revenue
ARDELYX, INC. FY2025 Key Financial MetricsXBRL
Revenue
$407M
▲ +22.1% YoY
Net Income
-$62M
▼ -57.4% YoY
Operating Margin
-10.1%
▼ -168bp YoY
Net Margin
-15.1%
▼ -339bp YoY
ROE
-36.9%
▼ -1431bp YoY
Total Assets
$502M
▲ +15.1% YoY
EPS (Diluted)
$-0.26
▼ -52.9% YoY
Operating Cash Flow
-$42M
▲ +5.2% YoY
Source: XBRL data from ARDELYX, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on ARDELYX, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.